» Articles » PMID: 19944723

Neuroprotection by Biodegradable PAMAM Ester (e-PAM-R)-mediated HMGB1 SiRNA Delivery in Primary Cortical Cultures and in the Postischemic Brain

Overview
Specialty Pharmacology
Date 2009 Dec 1
PMID 19944723
Citations 38
Authors
Affiliations
Soon will be listed here.
Abstract

Although RNA interference (RNAi)-mediated gene silencing provides a powerful strategy for modulating specific gene functions, difficulties associated with siRNA delivery have impeded the development of efficient therapeutic applications. In particular, the efficacy of siRNA delivery into neurons has been limited by extremely low transfection efficiencies. e-PAM-R is a biodegradable arginine ester of PAMAM dendrimer, which is readily degradable under physiological conditions (pH 7.4, 37 degrees C). In the present study, we investigated the efficiency of siRNA delivery by e-PAM-R in primary cortical cultures and in rat brain. e-PAM-R/siRNA complexes showed high transfection efficiencies and low cytotoxicities in primary cortical cultures. Localization of fluorescence-tagged siRNA revealed that siRNA was delivered not only into the nucleus and cytoplasm, but also along the processes of the neuron. e-PAM-R/siRNA complex-mediated target gene reduction was observed in over 40% of cells and it was persistent for over 48 h. The potential use of e-PAM-R was demonstrated by gene knockdown after transfecting High mobility group box-1 (HMGB1, a novel cytokine-like molecule) siRNA into H(2)O(2)- or NMDA-treated primary cortical cultures. In these cells, HMGB1 siRNA delivery successfully reduced both basal and H(2)O(2)- or NMDA-induced HMGB1 levels, and as a result of that, neuronal cell death was significantly suppressed in both cases. Furthermore, we showed that e-PAM-R successfully delivered HMGB1 siRNA into the rat brain, wherein HMGB1 expression was depleted in over 40% of neurons and astrocytes of the normal brain. Moreover, e-PAM-R-mediated HMGB1 siRNA delivery notably reduced infarct volume in the postischemic rat brain, which is generated by occluding the middle cerebral artery for 60 min. These results indicate that e-PAM-R, a novel biodegradable nonviral gene carrier, offers an efficient means of transfecting siRNA into primary neuronal cells and in the brain and of performing siRNA-mediated gene knockdown.

Citing Articles

HMGB1: A New Target for Ischemic Stroke and Hemorrhagic Transformation.

Li J, Wang Z, Li J, Zhao H, Ma Q Transl Stroke Res. 2024; .

PMID: 38740617 DOI: 10.1007/s12975-024-01258-5.


Nanomaterial-Based Drug Delivery Systems for Ischemic Stroke.

Jiang C, Zhou Y, Chen R, Yang M, Zhou H, Tang Z Pharmaceutics. 2023; 15(12).

PMID: 38140010 PMC: 10748360. DOI: 10.3390/pharmaceutics15122669.


Brain Gene Silencing with Cationic Amino-Capped Poly(ethylene glycol) Polyplexes.

Alamoudi A, Mendez P, Workman D, Schatzlein A, Uchegbu I Biomedicines. 2022; 10(9).

PMID: 36140283 PMC: 9496157. DOI: 10.3390/biomedicines10092182.


Nanoparticles in the diagnosis and treatment of vascular aging and related diseases.

Xu H, Li S, Liu Y Signal Transduct Target Ther. 2022; 7(1):231.

PMID: 35817770 PMC: 9272665. DOI: 10.1038/s41392-022-01082-z.


Advances of nano drug delivery system for the theranostics of ischemic stroke.

Lv W, Liu Y, Li S, Lv L, Lu H, Xin H J Nanobiotechnology. 2022; 20(1):248.

PMID: 35641956 PMC: 9153106. DOI: 10.1186/s12951-022-01450-5.